Navigation Links
Medicsight Announces Global Agreement With Alma IT Systems
Date:6/25/2009

NEW YORK, June 25 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE AMEX: MGT) and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, which assists radiologists in the early detection of disease, is pleased to announce it has signed a non-exclusive, software license and distribution agreement with Alma IT Systems ("Alma"). Alma is a leading developer of advanced digital medical imaging tools, across Europe and South America. This agreement will give Medicsight access to Alma's large and established installed base of radiology customers in key markets.

As part of this agreement Medicsight's ColonCAD API 4.0 software will be integrated into Alma's latest Colon viewer, a 3D visualization workstation which interprets computed tomographic colonography (CTC) image data. Alma is one of Spain's market leaders in medical imaging technology. It is anticipated that the new product will be offered to both clinicians and PACS customers via the ALMA 3D workstation and server-based client platforms.

Commenting on the partnership, Jacobo Gil de Biedma, co-founder and CEO of Alma IT Systems, said, "Alma is a market leader in medical imaging software in Spain and we are quickly gaining market share in Europe and South America. We are seeing a growing demand for CT colonography imaging tools. By developing the latest Alma Colon viewer with the integration of Medicsight's latest ColonCAD application, we can offer our clients complete, fast and reliable imaging technology and continue to consolidate the ALMA 3D platform as a one-stop solution."

Allan Rowley, Chief Executive of Medicsight, commented, "This agreement provides Medicsight with an ideal commercial opportunity to work with Alma and further extend our reach into the European and S
'/>"/>

SOURCE MGT Capital Investments, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CMS Decision - No Material Financial Impact to Medicsight
2. Medicsight PLC Provides Business Update
3. Medicsight PLC Restructures Management Team
4. MGT Capital Investments, Inc.: Failure to Satisfy a Continued Listing Rule Based on a Lack of Shareholder Meeting in 2008 and Medicsight Statement Regarding CMS Proposed Decision
5. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
6. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
7. Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008
8. Medicsight ColonCAD Technology Successfully Identified Cancer in 100% of Patients Included in Data Presented at ESGAR 2008
9. Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser
10. MGT Capital Investments, Inc. is Delighted with the Announcement of Medicsights Commercial Agreement with Toshiba PACS Division
11. Boston Scientific Announces Retirement of Jim Tobin and Appointment of Ray Elliott as New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... San Diego, CA (PRWEB) September 01, 2014 ... website daily regarding all the latest information from the ... , The US FDA announced on August 28, ... are recalled (Class I) as the device ... FDA, the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 ... into Heartbeat Experts’ perspectives on stakeholder ... , Download the flash report to speak ... any launching Diabetes product:, , ... an increasingly crowded market ,     Understanding ...
(Date:8/31/2014)... 31, 2014 Just in time for Washington’s ... only wild, sustainable Alaska Salmon, award winning chowder ... Duke's Green Lake location , Sunday, September 28, 2014 ... sample several ethnic salmon BBQ culinary delights. Live music will ... from Hawaii, Puerto Rico and Mexico will be featured. ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... ... and Insurance Services, a leading provider of information-based technology services to the ... in Louisiana and Texas in addition to its services that are provided ... headquartered in Hampton, New Hampshire and is owned by Medical Protective, part ...
... , , ARLINGTON, Va., ... that a panel of independent scientific experts convened by the ... a reproductive or developmental toxicant. After a thorough review ... Committee determined that bisphenol A should not be listed under ...
... WASHINGTON, July 15 On behalf of the nation,s mayors, ... commended President Barack Obama, the House of Representatives and the Senate ... transformative health care reform legislation. , ... times because they are not able to afford health insurance and, ...
... , SCOTTSDALE, Ariz., July 15 Grubb ... of America, Inc.) (the "REIT"), a self-managed non-traded real estate ... agreement (the "Agreement") to acquire a 16 building portfolio from ... transaction involves approximately 855,000 square feet of medical office and ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... , , , ... presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory ... and docetaxel did not provide a sufficient benefit-risk ... cancer. , , Women with locally advanced ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:California Expert Panel Concludes Bisphenol A is Not a Reproductive or Developmental Toxicant 2Health News:The Nation's Mayors Commend New Healthcare Reform Legislation 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6
(Date:8/29/2014)... Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... Court for the District of New Jersey ... company,s case against Sandoz, Inc. regarding United Therapeutics, Remodulin ... ruled that U.S. Patent No. 6,765,117 is both ... from marketing its generic product until the expiration of ...
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... YORK, Pa. , Aug. 29, 2014  Unilife ...  ASX: UNS) announced today that it intends to release ... and year ended June 30, 2014 after market trading ... Management has scheduled a conference call for 4:30 p.m. ... 10, 2014 at 6:30 a.m. AEST), to review the Company,s ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... CINCINNATI, July 7 Procter & Gamble Pharmaceuticals (P&GP) ... tablets, which are indicated for the treatment of moderately ... disease. UC involves inflammation of the lining of the ... followed by periods of remission. Moderately active UC is ...
... Tenn., July 6 /PRNewswire/ -- A Pebble Beach ... cure for multiple sclerosis. The researchers took home the top ... and the non-profit Band Against MS (BAMS) organization. The money ... at the University of Texas Health Science Center at ...
Cached Medicine Technology:Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 2Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 3Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 4Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets 5Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: